Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Queensland Health
AstraZeneca
Federal Trade Commission
Daiichi Sankyo
US Department of Justice
Covington
Cantor Fitzgerald

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022134

« Back to Dashboard

NDA 022134 describes LASTACAFT, which is a drug marketed by Allergan and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the LASTACAFT profile page.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.
Summary for 022134
Tradename:LASTACAFT
Applicant:Allergan
Ingredient:alcaftadine
Patents:1
Generic Entry Opportunity Date for 022134
Generic Entry Date for 022134*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022134
Suppliers and Packaging for NDA: 022134
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134 NDA Allergan, Inc. 0023-4290 0023-4290-01 1 BOTTLE, PLASTIC in 1 CARTON (0023-4290-01) > 1 mL in 1 BOTTLE, PLASTIC
LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134 NDA Allergan, Inc. 0023-4290 0023-4290-03 1 BOTTLE, PLASTIC in 1 CARTON (0023-4290-03) > 3 mL in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.25%
Approval Date:Jul 28, 2010TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 23, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Mallinckrodt
Federal Trade Commission
Cerilliant
Baxter
Harvard Business School
US Army
Julphar
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.